Andrew Parchman, MD
Hematology & Oncology · Cleveland, OHNPI 1497935316
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 84 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$200
- Genentech USA, Inc.$166
- Tempus AI, Inc$161
- Pfizer$154
- AstraZeneca$122
- Intuitive Surgical$118
- plus $1K from 28 others
Across 41 payments — averaging $17,510 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$378K
- E.r. Squibb & Sons, L.L.C.$307K
- Janssen Research & Development, LLC$33K
What the payments were for
- Food & beverage$1,92097%
- Education$653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $200 |
| Genentech USA, Inc. | 2 | $166 |
| Tempus AI, Inc | 2 | $161 |
| Pfizer | 9 | $154 |
| AstraZeneca | 6 | $122 |
| Intuitive Surgical | 1 | $118 |
| Galvanize Therapeutics, Inc | 1 | $116 |
| Seagen Inc. | 4 | $78 |
| Amgen | 5 | $77 |
| Merck | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Astellas Pharma US Inc | 4 | $60 |
| AVEO Pharmaceuticals, Inc. | 3 | $60 |
| Lilly USA, LLC | 3 | $48 |
| EMD Serono, Inc. | 2 | $45 |
| Gilead(2 entities) | 3 | $41 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $32 |
| AbbVie | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Mirati Therapeutics, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Incyte Corporation | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Accord Healthcare, Inc. | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Immunogen, Inc. | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Array Biopharma Inc | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $16 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$150
- Da Vinci Surgical System$118
- ALIYA SYSTEM$116
How this compares
$1,985 in reported general payments places this provider in the 45th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 26 | $417,531 |
| InlytaAxitinib | 17 | $318,384 |
| RetevmoSelpercatinib | 13 | $299,640 |
| PomalystPomalidomide | 13 | $292,240 |
| TagrissoOsimertinib Mesylate | 13 | $220,028 |
| BrukinsaZanubrutinib | 13 | $196,847 |
| JakafiRuxolitinib Phosphate | 12 | $189,151 |
| CalquenceAcalabrutinib Maleate | 12 | $173,352 |
| IbrancePalbociclib | 11 | $165,258 |
| TasignaNilotinib Hcl | 13 | $133,577 |
| Lenalidomide | 15 | $121,076 |
| EliquisApixaban | 128 | $92,144 |
| XareltoRivaroxaban | 82 | $70,200 |
| Imatinib Mesylate | 13 | $7,427 |
| Abiraterone Acetate | 18 | $3,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerInlyta, Ibrance, Eliquis | $154 | $575,786156 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $32 | $417,53126 claims |
| AstraZenecaTagrisso, Calquence | $122 | $393,38025 claims |
| Lilly USA, LLCRetevmo | $48 | $299,64013 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $64 | $292,24013 claims |
| Incyte CorporationJakafi | $24 | $189,15112 claims |
| NovartisTasigna | $200 | $133,57713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.